Thomas J. Schuetz, M.D., Ph.D.

Thomas J. Schuetz, M.D., Ph.D.

Chief Executive OfficeratCompass Therapeutics· In proxies 2022–2025

Pay in FY2025+65% from the year before · Compass Therapeutics stock +270.3% the same year

Thomas J. Schuetz, M.D., Ph.D. was paid $5.1M in FY2025 (Dec), up 65%. Compass Therapeutics stock rose 270.3% that year.

Pay$100 in the stock at the end of FY21 → $546
Pay is from the Summary Compensation Table of each Compass Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Compass TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role -75%

Roles come from the proxy statements of each company.

Boards1

  • Compass TherapeuticsDirector · 9 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?